– Robust preclinical data support Exelixis’ clinical development of XL114, with phase 1 trial in Non-Hodgkin’s lymphoma expected to begin in the coming months – – Exelixis will make an option exercise
– Phase 1 clinical trial expected to begin in Q1 2021 – Under the terms of the companies’ agreement, Exelixis will make an option exercise payment of $12 million to
Exelixis and Aurigene Announce That Promising Preclinical Data to Be Presented at the ENA Symposium Support the Clinical Development of a Novel CDK7 Inhibitor – Detailed characterization of an oral
PRESS RELEASE Aurigene Announces First Patient Dosed with AUR101 in Phase II Study in Patients with Moderate to Severe Psoriasis Bangalore, February 17, 2020 — Aurigene, a development stage
PRESS RELEASE Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170 – Aurigene to fund and conduct a Phase 2b/3 randomized study of CA-170 in
ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into an exclusive collaboration, option and license agreement with Aurigene Discovery Technologies Limited (Aurigene), the India-based discovery biotechnology
– Phase 1 data from the study expected to be available by December 2018 Aurigene, a biotechnology company focused on discovering and developing drugs for oncology and inflammatory disorders,
Aurigene will be presenting multiple posters at the annual American Association for Cancer Research (AACR) Conference scheduled to be held in Chicago, Illinois from April 14-18 More information about the
The Phase 2 trial is the result of the initial safety data and preliminary evidence of clinical benefit observed in the trial. Aurigene Discovery Technologies Limited, a wholly owned subsidiary
Aurigene will be participating at the annual American Society of Hematology (ASH) Conference scheduled to be held in Atlanta, Georgia from December 9-12. More information about the conference can be
